Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105429 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01105429 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 56 participants.
The verdict
NCT01105429, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug, as well as the amount of study drug in the blood, in subjects with type 2 diabetes.
Interventions
- DRUG BMS-820132
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105429
The ClinicalTrials.gov registry entry for NCT01105429 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-820132 is the first listed.
NCT01105429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01105429 about?
NCT01105429 is a clinical study titled "Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes". BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of single doses of the investigational new drug, as well as the amount of study drug in the blood, in subjects with typ...
What is the current status of trial NCT01105429?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2010-05. Estimated completion is 2010-10.
What interventions are being tested in trial NCT01105429?
The interventions under investigation include: BMS-820132 (DRUG).
Who is sponsoring clinical trial NCT01105429?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.